Evidence-basedEditor-reviewedCited sourcesUpdated regularly
Other Ingredients

SAM-e

Also known as: S-Adenosylmethionine, S-Adenosyl-L-methionine, SAMe, Ademetionine

The body's universal methyl donor — an actual antidepressant drug in Europe, with joint and liver evidence too.

In short

S-Adenosylmethionine (SAM-e) is a molecule the body makes from methionine and ATP that serves as the universal donor of methyl groups — the chemical 'switches' used in over a hundred reactions, including the synthesis of serotonin, dopamine, and norepinephrine. This centrality explains its clinical reach: in Europe it is a prescription antidepressant, with meta-analyses finding efficacy comparable to tricyclic antidepressants for depression; it has randomized-trial evidence for osteoarthritis pain (similar to NSAIDs but slower); and it is used intravenously for cholestatic liver disease. In the US it is sold as a supplement, usually in a stabilized salt form. It is generally well tolerated; the main cautions are bipolar-mania induction risk and gastrointestinal effects.

  • Universal methyl donor; made from methionine + ATP
  • European prescription antidepressant; US supplement
  • Meta-analyses: depression efficacy comparable to older drugs
  • Also evidenced for osteoarthritis and cholestasis

What is SAM-e?

SAM-e is a supplement in America and a medicine in Europe — a status gap that tells you something about both the molecule and the markets. As the body's universal methyl donor, it sits upstream of serotonin, dopamine, and countless other reactions, which gives it drug-like reach: depression, joint pain, and liver cholestasis all carry randomized-trial evidence. The European psychiatrists who prescribe it and the American supplement users who take it are relying on the same chemistry; what differs is oversight, dosing discipline, and the warnings attached.

Where it comes from

Natural sources

  • Endogenously synthesized from methionine and ATP
  • Dietary methionine (protein) is the raw material
  • Commercial forms: stabilized salts (tosylate, butanedisulfonate) for stability

How it's made

Enteric-coated tablets typical: 200–400 mg; clinical doses 400–1,600 mg/day.

What it does in products

  • Methyl donation to DNA, phospholipids, and proteins
  • Neurotransmitter synthesis support (serotonin, dopamine)
  • Polyamine and glutathione pathway support
  • Joint-cartilage proteoglycan synthesis

Benefits

Depression

strong evidence

Meta-analyses of randomized trials find SAM-e comparable to tricyclic antidepressants and superior to placebo, particularly in mild-to-moderate depression.

Osteoarthritis

strong evidence

Trials show pain and function improvements comparable to NSAIDs, with slower onset (weeks) and a better gastrointestinal safety profile.

Liver support

moderate evidence

Used intravenously for intrahepatic cholestasis of pregnancy and liver disease; oral evidence is more limited.

Side effects & safety

Nausea and GI upset (common)Dose-dependent; enteric coating and food reduce it.
Insomnia, anxiety, and agitation (uncommon)Activating effect; avoid evening dosing.
Mania induction in bipolar disorder (rare)Well documented — a reason for medical supervision in mood disorders.

Safety considerations

  • Intravenous SAM-e is used clinically in cholestasis of pregnancy in some countries; oral supplement use should be clinician-supervised.
  • Antidepressants (SSRIs, MAOIs, tricyclics) — additive serotonergic effects; do not combine without supervision
  • Levodopa — SAM-e may reduce effectiveness
  • Not for: Bipolar disorder (mania risk)
  • Not for: Concurrent serotonergic medication without medical oversight

How it's used

In supplements

400–1,600 mg/day in divided doses, morning and midday (activating); start at 200–400 mg and titrate. Effects typically at 2–6 weeks.

In skincare

Not a topical ingredient.

Regulatory status

  • Sold as a dietary supplement in the US; registered as a prescription drug for depression and liver disease in several European countries.
  • Not applicable.

Popular products containing SAM-e

  • Nature Made SAM-e Complete — 400 mg enteric-coated tabletsNature Made · Supplement
  • Doctor's Best SAM-e 400 — Butanedisulfonate formDoctor's Best · Supplement
  • Jarrow Formulas SAM-e 400 — Enteric-coated, clinically used doseJarrow Formulas · Supplement

Product names and brands are shown for reference and belong to their respective owners.

Why a methyl donor treats depression

Catecholamine and serotonin synthesis consume methyl groups, and depressed populations often show impaired methylation status. SAM-e directly donates methyl groups to these pathways and increases neurotransmitter turnover — a mechanism overlapping with, but distinct from, conventional antidepressants. This likely explains both its efficacy and its rapid (1–2 week) onset in some trials.

The supplement-drug divide

European regulators license SAM-e at 1,600 mg/day for depression with psychiatric oversight; US consumers buy the same molecule at Costco. The molecule is the same — but the US supplement pathway means no formal diagnosis, dosing supervision, or mania screening, which matters because SAM-e is genuinely mood-active, not a wellness placebo.

Frequently asked questions

Can SAM-e replace my antidepressant?

Not without your prescriber. SAM-e has real antidepressant evidence and real interaction risks with other serotonergic drugs — transitions require supervision.

When is the best time to take SAM-e?

Morning and midday on an empty stomach (enteric forms). It is activating — evening dosing commonly causes insomnia.

How long before it works?

Some trials show mood effects within 1–2 weeks; joint benefits build over 4–8 weeks. Most clinical assessments use 4–6 weeks.

The bottom line

SAM-e is a drug-grade molecule wearing supplement clothing in the US — with genuine, meta-analyzed evidence for depression and osteoarthritis, and warnings that deserve the same respect as its benefits.

References

  1. S-adenosylmethionine for depression: meta-analysis. American Journal of Clinical Nutrition. https://pubmed.ncbi.nlm.nih.gov/20519442/
  2. SAM-e in osteoarthritis: randomized trials. PubMed Central. https://pubmed.ncbi.nlm.nih.gov/27290675/
  3. SAM-e — NCCIH. NCCIH. https://www.nccih.nih.gov/health/sadenosyllmethionine-same